To the Editor: Cholangiocarcinoma (CCA) is a biliary tract tumor that is notoriously diffi cult to diagnose. Surgical resection is associated with a 20-40% 5-year survival rate. Liver transplantation with neoadjuvant therapy for unresectable perihilar CCA (pCCA) can be a curative option with a 5-year survival rate of >70%, and is off ered by a growing number of medical centers ( 1 ) . Advanced pCCA with extrahepatic metastasis is a contraindication for liver transplantation. Any undiagnosed metastatic disease will have an accelerated course upon initiation of immunosuppressive therapy aft er liver transplantation. In a recent article, Tellez-Avila et al. ( 2 ) from Mexico report the high sensitivity of endoscopic ultrasound (EUS)-guided tissue acquisition for pCCA. While test performance is reasonable, the use of this technique in pCCA is fraught with an inappropriately high rate of needle tract tumor seeding ( 3 ) . Th e data on tract seeding rates in the presented study are missing. Th e study ( 2 ) echoes the recent report from the Indiana University group stating that EUS-guided fi ne-needle aspiration (FNA) did not infl uence CCA recurrence and patient survival aft er the curative-intent surgery ( 4 ). However, the median progression-free survival in the study from Indiana was 17.8 months (95% CI, 14.5-22.8), which is too dismal and short a time to observe the eff ect of tumor tract seeding on outcomes. Th e aim of liver transplantation is to dramatically improve the survival of patients with disease that otherwise would be lethal. A study from our institution indicates that during the tumor staging procedure 83% of patients with a history of a positive EUS-directed needle aspiration are found to have peritoneal metastasis ( 5 ). More impressively, the metastases were along the needle track, implying seeding during the EUS-directed biopsy. We should be diligent in using other diagnostic modalities, including imaging studies, cholangiography, and advanced cytological evaluation with fl uorescent in situ hybridization for polysomy, in making the diagnosis of pCCA. In centers and countries that can off er liver transplantation for pCCA, we need to be clear that EUS FNA of a hilar mass (pCCA) should be discouraged. EUS FNA remains a very important tool in the sampling of lymph nodes and other extra hepatic sites for pCCA staging. Th e medical community should be aware of the high risk associated with direct tumor tissue sampling with EUS FNA, as this can be detrimental to patient outcomes.
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